atrial fibrillation, non valvular, anticoagulants, oral direct thrombin inhibitors, risk of bleeding, elder patients
DISEASE INTERVENTION COMPARISON RESULTS
Circulation. 2011 May 31;123(21):2363-72 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, non valvular, anticoagulants, oral direct thrombin inhibitors, risk of bleeding, elder patients The Use of
oral direct thrombin inhibitors, dabigatran, 110 or 150 mg twice daily fixed dose
As Treatment, Chronic
Is equal Than
warfarin
To risk of major bleeding, in patients >75 years, with the 110mg dose (4.43% dabigatran VS 4.37% warfarin) but a trend to more bleedings with 150mg dose (5.1% dabigatran versus 4.4% warfarin). Both doses had less bleedings in <75 years old